Results 141 to 150 of about 19,271 (221)

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1160-1167, February 2026.
Abstract Aims Targeting the glucose dependent insulinotropic polypeptide receptor (GIPR) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporated into drugs like tirzepatide and maridebart cafraglutide, have paradoxically both shown ...
Iona Davies, Alexandra Turland, Hanh Duyen Tran, Carissa Wong, Olivier Cahn, Cecilia Dunsterville, Yichang Sun, Yilin Xiao, Kevin G. Murphy, Stephen R. Bloom, Ben Jones, Tricia M. M. Tan   +11 more
wiley   +1 more source

Tirzepatide - role in obesity, health and physical wellness. Information overview

Quality in Sport
Nowadays there is an increasing number of people with overweight and obesity all around the world. Unhealthy food, sweets and fast foods are available everywhere, that causes self-perpetuating problem. Food restriction is an obvious treatment, but it is
Anna Hanslik, Magdalena Mendak, Agata Białek, Agnieszka Walczak, Adrian Hovagimyan, Monika Olszanecka, Tomasz Olszanecki   +6 more
doaj   +1 more source

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan, Hongwei Jiang, Yi Feng, Suijun Wang, Jin Zhang, Zhongjing Wang, Yusen Zhou, Fangqiong Li, Zhanhui Zhang, Yaming Li, Liming Chen   +10 more
wiley   +1 more source

The novel adiponectin-resistin (AR) and insulin resistance (IR~AR~) indexes [PDF]

, 2010
Serum hypoadiponectinemia and hyperrestinemia independently links insulin resistance to type 2 diabetes (T2DM) and metabolic syndrome (MS). Thus, the aim of this study was propose a novel adiponectin-resistin (AR) index by unifying the effect of ...
Cia-Hin Lau, Sekaran Muniandy
core   +1 more source

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT‐J trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1278-1287, February 2026.
Abstract Aims This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. Materials and Methods This was a prespecified subgroup analysis of the SURMOUNT‐J trial.
Koutaro Yokote, Yasushi Fukushima, Tomotaka Shingaki, Tomonori Oura, Wataru Ogawa   +4 more
wiley   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source

Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1508-1516, February 2026.
Abstract Aims Ramadan fasting poses challenges for patients with type 2 diabetes mellitus (T2DM) due to increased risks of hypoglycemia and metabolic fluctuations. Tirzepatide, a dual GIP/GLP‐1 receptor agonist, has shown marked efficacy in glycemic control and weight reduction.
Muhammad Hafizur Rahman, Shahjada Selim, Faria Afsana, Md. Azizul Hoque, M. Saifuddin, Md. Shah Alam, Mirza Sharifuzzaman, Mohmmad Abdul Hannan, Md. Nazmul Hasan, A. B. M. Kamrul‐Hasan, Marufa Mustari, Afsar Ahammed   +11 more
wiley   +1 more source

Alteraciones en el metabolismo de la glucosa en estado de resistencia a insulina y diabetes tipo 2: acción normalizadora del GLP-1 y de la Exedina -4 [PDF]

, 2010
Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología.
Moreno Pérez, Paola
core   +1 more source

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. [PDF]

J Lipid Atheroscler, 2023
Cho YK, La Lee Y, Jung CH.
europepmc   +1 more source

Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. [PDF]

Nat Metab, 2023
Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, Gutgesell RM, Bakhti M, Bastidas-Ponce A, Czarnecki O, Makris K, Lickert H, Feuchtinger A, Tost M, Coupland C, Ständer L, Akindehin S, Prakash S, Abrar F, Castelino RL, He Y, Knerr PJ, Yang B, Hogendorf WFJ, Zhang S, Hofmann SM, Finan B, DiMarchi RD, Tschöp MH, Douros JD, Müller TD.   +30 more
europepmc   +1 more source